Design and synthesis of bioreductive prodrugs of class I histone deacetylase inhibitors and their biological evaluation in virally transfected acute myeloid leukemia cells

被引:1
|
作者
Abdelsalam, Mohamed [1 ,2 ]
Zmyslia, Mariia [3 ]
Schmidtkunz, Karin [4 ]
Vecchio, Anita [1 ]
Hilscher, Sebastian [5 ]
Ibrahim, Hany S. [1 ,6 ]
Schutkowski, Mike [5 ]
Jung, Manfred [4 ,7 ]
Jessen-Trefzer, Claudia [3 ,8 ]
Sippl, Wolfgang [1 ,9 ]
机构
[1] Martin Luther Univ Halle Wittenberg, Dept Med Chem, Halle, Germany
[2] Alexandria Univ, Fac Pharm, Dept Pharmaceut Chem, Alexandria, Egypt
[3] Univ Freiburg, Inst Organ Chem, Freiburg, Germany
[4] Univ Freiburg, Inst Pharmaceut Sci, Freiburg, Germany
[5] Martin Luther Univ Halle Wittenberg, Inst Biochem, Dept Enzymol, Halle, Germany
[6] Egyptian Russian Univ, Fac Pharm, Dept Pharmaceut Chem, Cairo, Egypt
[7] Univ Freiburg, CIBSS Ctr Integrat Biol Signalling Studies, Freiburg, Germany
[8] Univ Freiburg, Inst Organ Chem, D-79104 Freiburg, Germany
[9] Martin Luther Univ Halle Wittenberg, Inst Pharm, Dept Med Chem, D-06120 Halle, Germany
关键词
epigenetics; HDACs; hypoxia; nitroreductases; prodrugs; NITROREDUCTASE; HYPOXIA; ENZYME; GDEPT;
D O I
10.1002/ardp.202300536
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Although histone deacetylase (HDAC) inhibitors show promise in treating various types of hematologic malignancies, they have some limitations, including poor pharmacokinetics and off-target side effects. Prodrug design has shown promise as an approach to improve pharmacokinetic properties and to improve target tissue specificity. In this work, several bioreductive prodrugs for class I HDACs were designed based on known selective HDAC inhibitors. The zinc-binding group of the HDAC inhibitors was masked with various nitroarylmethyl residues to make them substrates of nitroreductase (NTR). The developed prodrugs showed weak HDAC inhibitory activity compared to their parent inhibitors. The prodrugs were tested against wild-type and NTR-transfected THP1 cells. Cellular assays showed that both 2-nitroimidazole-based prodrugs 5 and 6 were best activated by the NTR and exhibited potent activity against NTR-THP1 cells. Compound 6 showed the highest cellular activity (GI50 = 77 nM) and exhibited moderate selectivity. Moreover, activation of prodrug 6 by NTR was confirmed by liquid chromatography-mass spectrometry analysis, which showed the release of the parent inhibitor after incubation with Escherichia coli NTR. Thus, compound 6 can be considered a novel prodrug selective for class I HDACs, which could be used as a good starting point for increasing selectivity and for further optimization. A new series of prodrugs for class I histone deacetylases (HDACs) was designed and synthesized by masking the zinc-binding group of reported HDAC1-3 inhibitors with different nitroaromatic moieties. Among these prodrugs, compound 6 showed the most potent inhibitory activity against nitroreductase (NTR)-transfected leukemic cells. Liquid chromatography-mass spectrometry analysis confirmed the activation of compound 6 and showed the release of its parent inhibitor after incubation with NTR.image
引用
下载
收藏
页数:14
相关论文
共 50 条
  • [1] Design, Synthesis, and Biological Evaluation of New Urushiol Derivatives as Potent Class I Histone Deacetylase Inhibitors
    Zhou, Hao
    Qi, Zhiwen
    Liu, Danyang
    Xue, Xingyin
    Wang, Chengzhang
    CHEMBIOCHEM, 2023,
  • [2] Development of allosteric hydrazide-containing class I histone deacetylase inhibitors for use in acute myeloid leukemia
    McClure, Jesse
    Zhang, Cheng
    Inks, Elizabeth
    Peterson, Yuri
    Li, Jiaying
    Chou, C. James
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [3] Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia
    McClure, Jesse J.
    Zhang, Cheng
    Inks, Elizabeth S.
    Peterson, Yuri K.
    Li, Jiaying
    Chou, C. James
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (21) : 9942 - 9959
  • [4] Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (sirtuin) inhibitors
    Mai, A
    Massa, S
    Lavu, S
    Pezzi, R
    Simeoni, S
    Ragno, R
    Mariotti, FR
    Chiani, F
    Camilloni, G
    Sinclair, DA
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (24) : 7789 - 7795
  • [5] Design and synthesis of a novel class of histone deacetylase inhibitors
    Lavoie, R
    Bouchain, G
    Frechette, S
    Woo, SH
    Abou Khalil, E
    Leit, S
    Fournel, M
    Yan, PT
    Trachy-Bourget, MC
    Beaulieu, C
    Li, ZM
    Besterman, J
    Delorme, D
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (21) : 2847 - 2850
  • [6] Design, synthesis, and biological activity of folate receptor-targeted prodrugs of thiolate histone deacetylase inhibitors
    Suzuki, Takayoshi
    Hisakawa, Shinya
    Itoh, Yukihiro
    Suzuki, Nobuaki
    Takahashi, Katsumasa
    Kawahata, Masatoshi
    Yamaguchi, Kentaro
    Nakagawa, Hidehiko
    Miyata, Naoki
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (15) : 4208 - 4212
  • [7] Chiral histone deacetylase inhibitors: Synthesis and biological evaluation
    Onate, Alma
    Tucker, Janelle
    Hogle, Emily
    Do, Thuy
    Thowfeik, Fathima
    Merino, Edward
    Ma, Lili
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [8] Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
    Quintas-Cardama, A.
    Santos, F. P. S.
    Garcia-Manero, G.
    LEUKEMIA, 2011, 25 (02) : 226 - 235
  • [9] Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
    A Quintás-Cardama
    F P S Santos
    G Garcia-Manero
    Leukemia, 2011, 25 : 226 - 235
  • [10] Design, synthesis, and biological evaluation of novel histone deacetylase 6 selective inhibitors
    Zhang, Tianyi
    Zhao, Xiaoyan
    Sun, Xiangpei
    Tian, Wei
    Wang, Chongqing
    Wang, Mingping
    Zhang, Yi
    Chen, Xin
    Zheng, Canhui
    JOURNAL OF SAUDI CHEMICAL SOCIETY, 2022, 26 (03)